No Data
Weak Statutory Earnings May Not Tell The Whole Story For Shanghai Titan Scientific (SHSE:688133)
Zheshang: Innovative drugs and blood products sectors may benefit from slow demand recovery on the demand side.
Zheshang has released research reports stating that the transition of old and new dynamics in the pharmaceutical industry will continue in the future. Areas with innovative drugs, supply-side structural reform, or a good layout (innovative drugs supporting industry chain, large infusion solutions, potent anaesthetics, blood products, pharmaceutical circulation, traditional Chinese medicine OTC) could benefit from the slow recovery on the demand side, potentially showing better growth prospects.
shanghai titan scientific co.,ltd. (688133.SH): tianjin Chuangfeng and its concerted action persons hold a total shareholding of less than 5%.
shanghai titan scientific co.,ltd. (688133.SH) announced that the company recently received a notice from tianjin chuangfeng and its concerted action person: Ning...
Titan Technology: Titan Tech Third Quarter 2024 Report
Titan Technology 2024 Third Quarter Report
shanghai titan scientific co.,ltd. (688133.SH) released its performance for the first three quarters, with a net income of 9.7079 million yuan, a year-on-year decrease of 86.49%.
shanghai titan scientific co.,ltd. (688133.SH) released the third quarter report of 2024, with the company's revenue for the first three quarters reaching 21...
Shanghai Titan Scientific (SHSE:688133) Could Be Struggling To Allocate CapitalNo Data
No Data
